Clinical aspects of imatinib therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Imatinib is an inhibitor of the ABL, platelet-derived growth factor receptors, and KIT tyrosine kinases. Given the pathogenetic role of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, this was the first disease selected for clinical trials with imatinib. In the clinical trials, patients in all phases of the disease responded to imatinib and experienced minimal toxicity. Responses in patients with chronic phase disease have been durable, thus far. Clinical trials with imatinib were expanded and there are now examples of malignancies driven by each of the targets of imatinib where remarkable results have been seen. The rationale for the use of imatinib in these various diseases and the clinical trial results will be reviewed.

Original languageEnglish (US)
Title of host publicationInhibitors of Protein Kinases and Protein Phosphates
EditorsLorenzo Pinna, Patricia Cohen
Pages391-410
Number of pages20
DOIs
StatePublished - Dec 1 2005

Publication series

NameHandbook of Experimental Pharmacology
Volume167
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Keywords

  • BCR-ABL
  • CML
  • Imatinib

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Clinical aspects of imatinib therapy'. Together they form a unique fingerprint.

  • Cite this

    Druker, B. J. (2005). Clinical aspects of imatinib therapy. In L. Pinna, & P. Cohen (Eds.), Inhibitors of Protein Kinases and Protein Phosphates (pp. 391-410). (Handbook of Experimental Pharmacology; Vol. 167). https://doi.org/10.1007/3-540-26670-4-14